rss
Postgrad Med J 2004;80:320-327 doi:10.1136/pgmj.2003.013508
  • Review

Evolving immunotherapeutic strategies in bladder and renal cancer

  1. T R L Griffiths,
  2. J K Mellon
  1. Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester General Hospital, Leicester, UK
  1. Correspondence to:
 Mr T R L Griffiths
 Department of Cancer Studies and Molecular Medicine, University of Leicester, Clinical Sciences Unit, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK; TRLG1le.ac.uk
  • Received 7 August 2003
  • Accepted 3 November 2003

Abstract

For patients with urological cancers, immunotherapy is currently a treatment option for metastatic renal cell carcinoma, and those with “high risk” superficial bladder cancers. In this review, our current understanding of tumour immune escape is discussed. The principles and role of current immunotherapies for these tumours are described, and new areas of immunotherapeutic promise are highlighted.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.